-
公开(公告)号：US20100061970A1
公开(公告)日：2010-03-11
申请号：US12514410
申请日：2007-11-12
申请人： Kurt Bachmaier , Asrar B. Malik
发明人： Kurt Bachmaier , Asrar B. Malik
CPC分类号： A61K38/19 , A61K38/53 , A61K2300/00
摘要： Methods of treating endotoxin-mediated disorders are provided.
摘要翻译： 提供了治疗内毒素介导的病症的方法。
-
公开(公告)号：US08168176B2
公开(公告)日：2012-05-01
申请号：US12514410
申请日：2007-11-12
申请人： Kurt Bachmaier , Asrar B. Malik
发明人： Kurt Bachmaier , Asrar B. Malik
CPC分类号： A61K38/19 , A61K38/53 , A61K2300/00
摘要： Methods of treating endotoxin-mediated disorders are provided.
摘要翻译： 提供了治疗内毒素介导的病症的方法。
-
公开(公告)号：US08067389B2
公开(公告)日：2011-11-29
申请号：US12505911
申请日：2009-07-20
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.
摘要翻译： 本申请涉及TGF-bgr的II型受体的基于siRNA的沉默。 靶向该受体的siRNA消除受体蛋白和转录物，TGFβb介导的过程如纤连蛋白装配和细胞迁移也受到抑制，本发明的分子有效降低炎症反应和基质沉积。 这些研究结果表明，siRNA可以在体外和体内成功传递，以调节TGF-bgr; II型受体水平和调节伤口反应。 利用本发明的发现的方法和组合物具有广泛的应用，从眼睛疾病的治疗延伸到整个身体的其他器官和组织。
-
公开(公告)号：US07429563B2
公开(公告)日：2008-09-30
申请号：US11514578
申请日：2006-09-01
CPC分类号： A61K48/0008 , A61K38/00 , A61K47/62 , A61K47/66 , B82Y5/00 , C12N9/0065
摘要： The present invention is directed to compositions based on myeloperoxidase amino acid sequence which may be used as therapeutic agents or as delivery vehicles for the delivery of other therapeutic agents.
摘要翻译： 本发明涉及可用作治疗剂或作为递送其它治疗剂的递送载体的基于髓过氧化物酶氨基酸序列的组合物。
-
5.发明授权Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion 有权用于治疗肺损伤，哮喘，过敏反应，血管性水肿，全身血管通透性综合征和鼻充血的肽组合物和方法公开(公告)号：US09248198B2
公开(公告)日：2016-02-02
申请号：US14105385
申请日：2012-06-13
CPC分类号： A61K47/48276 , A61K38/00 , A61K38/1709 , C07K7/06 , C07K7/08 , C07K14/705 , C07K2319/033 , C07K2319/10
摘要： Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
摘要翻译： 本文提供了末端结合蛋白3（EB3）和1,4,5-三磷酸肌醇受体3型（IP3R3）之间相互作用的肽抑制剂。 还提供了用于治疗肺损伤的方法和材料，包括急性肺损伤，其可以包括肺血管渗透性过高，血管渗漏，水肿发展，哮喘，过敏反应，血管性水肿，全身血管通透性综合征和鼻充血。
-
公开(公告)号：US20110171193A1
公开(公告)日：2011-07-14
申请号：US12996712
申请日：2009-06-12
申请人： You-Yang Zhao , Asrar B. Malik
发明人： You-Yang Zhao , Asrar B. Malik
IPC分类号： A61K31/555 , A61K31/522 , A61K31/352 , A61K31/34 , A61K31/195 , A61K31/33 , A61K31/05 , A61K31/19 , A61K31/445 , A61K38/44 , A61K31/075 , A61K31/56 , A61K31/12 , A61K31/03 , A61K33/26 , A61K33/34 , A61K31/405 , A61K31/192 , A61K31/20 , A61K33/40 , A61K38/00 , A61K31/708 , A61K31/497 , A61K31/505 , A61K31/4985 , G01N33/53 , A61P9/12
CPC分类号： A61K31/555
摘要： Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy.
摘要翻译： 本文提供了用于治疗受试者的肺动脉高压（PH）的方法和材料。 本文还提供了通过检测PH标记来诊断是否具有PH的方法。 已经鉴定了PKG肺动脉高压标记物，并且可用于预测PH疾病进展并评估受试者对PH治疗的反应。
-
公开(公告)号：US08137968B2
公开(公告)日：2012-03-20
申请号：US12038020
申请日：2008-02-27
申请人： Kishore K. Wary , Yidan Zhao , Asrar B. Malik , You-Yang Zhao
发明人： Kishore K. Wary , Yidan Zhao , Asrar B. Malik , You-Yang Zhao
CPC分类号： C12N5/0692 , C12N2501/105 , C12N2501/115 , C12N2501/165 , C12N2501/39 , C12N2501/91
摘要： The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α5β1 integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial barrier function, induce productive wound healing and angiogenesis, and increase survival rate in acute lung injury (ALI).
摘要翻译： 本发明是一种制备基本纯净的内皮祖细胞群的方法，其中所述细胞表达Flk-1，CD34，α5和bgr1整联蛋白纤连蛋白和vWF，并表现出粘附表型，并使用其来降低其严重程度 肺损伤，预防肺水肿，恢复内皮屏障功能，诱导生产性伤口愈合和血管生成，并增加急性肺损伤（ALI）的存活率。
-
公开(公告)号：US20080206200A1
公开(公告)日：2008-08-28
申请号：US12038020
申请日：2008-02-27
申请人： Kishore K. Wary , Yidan Zhao , Asrar B. Malik , You-Yang Zhao
发明人： Kishore K. Wary , Yidan Zhao , Asrar B. Malik , You-Yang Zhao
CPC分类号： C12N5/0692 , C12N2501/105 , C12N2501/115 , C12N2501/165 , C12N2501/39 , C12N2501/91
摘要： The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α5β1 integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial barrier function, induce productive wound healing and angiogenesis, and increase survival rate in acute lung injury (ALI).
摘要翻译： 本发明是一种制备基本纯净的内皮祖细胞群的方法，其中所述细胞表达Flk-1，CD34，α5β1整联蛋白纤连蛋白，vWF和 表现出一种粘附表型，并使用该方法降低肺损伤的严重程度，预防肺水肿，恢复内皮屏障功能，诱导生产性伤口愈合和血管生成，并提高急性肺损伤（ALI）的存活率。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.017 秒)
